NimBio News
3 articles
growth-positive
The company has raised a total of $2 million for its non-invasive technology, helping those with Inflammatory Bowel Diseases.
NimBio has raised a total of $2 million to develop its AI-powered, non-invasive Inflammometer™ technology aimed at early detection of inflammation in patients with Inflammatory Bowel Diseases (IBD). The technology, which can be integrated into everyday devices like smartwatches, aims to predict flare-ups, potentially reducing hospitalizations by up to 50% and saving billions in healthcare costs. NimBio has formed strategic partnerships with Takeda, KU Leuven, and EIT Health to accelerate clinical validation and regulatory approval. The company plans to enter the market in 2026, focusing on hospitals, pharma companies, and digital health platforms.
growth-positive
NimBio is among the thirty most promising life science and healthtech start-ups in Europe!
NimBio has been recognized as one of the thirty most promising life science and healthtech start-ups in Europe, having been selected as a semifinalist in the 9th Edition of the EIT Health Catapult competition. This accolade follows their success in the EIT Health Open Innovation IBD Challenge. NimBios flagship product, the Inflammometer™, is a non-invasive technology aimed at early detection of flares in chronic inflammatory diseases, particularly Inflammatory Bowel Diseases (IBD). The EIT Health Catapult program offers a platform for start-ups to present their innovations to industry experts and investors, with the finals set for April 2025. The competition includes significant prizes, including a €30,000 award and in-kind support from major industry players.
growth-positive
השעון החכם שיתריע לפני התפרצות מחלות דלקתיות
Nimbio, a company founded in 2018, is developing a smart wristband designed to predict inflammatory disease flare-ups, focusing initially on Crohns and colitis. The device aims to provide non-invasive monitoring to improve patient quality of life and reduce healthcare burdens. Nimbio has completed a successful clinical trial with 26 patients and plans to expand testing. The company has raised $1.5 million from investors including eHealth Ventures and other angel investors. Nimbios business model involves a subscription fee for continuous monitoring, with plans to seek regulatory approval by 2025 and begin sales in 2026.
Investment
